Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cross-Induction of Anti-Complexing Protein Antibodies in Healthy Volunteers Treated With Botulinum Toxin
TCTR20250905005Phase 1Completed
- Sponsor
- Siriraj Hospital
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of neuronox, sponsored by Siriraj Hospital. Primary endpoint: Percentage of anti-complexing protein antibody at 180 days after treatment. Started Jun 2021; status: completed.
02
Drugs
neuronox
Beyond the preview
Go deeper on TCTR20250905005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250905005.